<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943785</url>
  </required_header>
  <id_info>
    <org_study_id>DU176B-C-U4001</org_study_id>
    <secondary_id>2016-003930-26</secondary_id>
    <nct_id>NCT02943785</nct_id>
  </id_info>
  <brief_title>Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)</brief_title>
  <official_title>Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chiltern International Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Daiichi Sankyo Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      When the upper chambers of a person's heart receive irregular electrical signals it causes
      abnormal rhythm in the heart beat. This is called atrial fibrillation.

      Atrial fibrillation increases the chance of having a heart attack or stroke. Some patients
      also get new heart valves using a catheter.

      Often doctors give patients a medicine called a vitamin K antagonist (VKA), because it is
      considered the standard care. This study will see how edoxaban compares to VKA in patients
      who got a new heart valve by using a catheter.

      The study will compare the two drugs for up to three years after heart valve replacement,
      looking at the drug's overall side effects (called adverse events) and major bleeding.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of Edoxaban in patients with atrial fibrillation (AF) and indication to chronic oral
      anticoagulation (OAC) after transcatheter aortic valve implantation (TAVI)

      Objective:

        -  To assess the effect of Edoxaban versus vitamin K antagonist (VKA) on net adverse
           clinical events (NACE), i.e., the composite of all-cause death, myocardial infarction
           (MI), ischemic stroke, systemic thromboembolism (SEE), valve thrombosis, and major
           bleeding (International Society on Thrombosis and Haemostasis [ISTH] definition).

        -  To assess the effect of Edoxaban versus VKA on major bleeding (ISTH definition).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants experiencing the described adverse event composite within 36 months</measure>
    <time_frame>within 36 months</time_frame>
    <description>Adverse event composite included all-cause death, myocardial infarction (MI), ischemic stroke, systemic embolic events (SEE), valve thrombosis, and major bleeding per definition of the International Society on Thrombosis and Haemostasis (ISTH].</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing major bleeding (ISTH definition)</measure>
    <time_frame>within 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants experiencing the described adverse event composite within 36 months</measure>
    <time_frame>within 36 months</time_frame>
    <description>This adverse event composite included all-cause death, myocardial infarction (MI), ischemic stroke, systemic embolic events (SEE), valve thrombosis, and major bleeding per definitions other than those of the International Society on Thrombosis and Haemostasis (ISTH]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing major bleeding per other than ISTH definition</measure>
    <time_frame>within 36 months</time_frame>
    <description>Other than ISTH definitions include Thrombolysis in Myocardial Infarction (TIMI) and Bleeding Academic Research Consortium (BARC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing stroke (ischemic, hemorrhagic, or undetermined)</measure>
    <time_frame>Baseline to 36 months</time_frame>
    <description>Description: Categories will include Any Stroke, Fatal Stroke, Non-fatal Stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants experiencing systemic embolic events (SEE)</measure>
    <time_frame>Baseline to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Edoxaban-based Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Edoxaban-based regimen 60 mg and 30 mg film coated tablet for once-daily oral use, and 15 mg film coated tablet for transitioning at end of treatment. Dosing must follow the locally approved label.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VKA-based regimen oral VKA tablets as selected and provided by the site and used in accordance with the local label. The Investigator will monitor the patient and adjust the VKA dose to maintain the dose within target.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban-based Regimen</intervention_name>
    <description>15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)</description>
    <arm_group_label>Edoxaban-based Regimen</arm_group_label>
    <other_name>Savaysa</other_name>
    <other_name>Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the United States (with anti-platelet therapy pre-declared at randomization if prescribed).</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Coumadin</other_name>
    <other_name>Jantoven</other_name>
    <other_name>Marevan</other_name>
    <other_name>Warfarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in Belgium</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Warfarin</other_name>
    <other_name>Phenprocoumon</other_name>
    <other_name>Acenocoumarol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in Austria and Switzerland</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Phenprocoumon</other_name>
    <other_name>Acenocoumarol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in France</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Warfarin</other_name>
    <other_name>Fluindione</other_name>
    <other_name>Acenocoumarol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in Germany and the Netherlands</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Warfarin</other_name>
    <other_name>Phenprocoumon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in Italy and Spain</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Warfarin</other_name>
    <other_name>Acenocoumarol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in the United Kingdom</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Warfarin</other_name>
    <other_name>Acenocoumarol</other_name>
    <other_name>Phenindione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in any other country where patients participate</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Other Approved VKA Product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VKA-based Regimen</intervention_name>
    <description>Dosed at INR levels. Standard of Care treatment in Canada</description>
    <arm_group_label>VKA-based Regimen</arm_group_label>
    <other_name>Apo-warfarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anti-platelet Therapy</intervention_name>
    <description>Anti-platelet therapy if prescribed - Type and duration of antiplatelet agent must be pre-declared at randomization, with antithrombotic agent (ASA) 75-100 mg/day or generic/branded clopidogrel 75 mg/day (chronic therapy following loading dose) as the preferred agents.</description>
    <arm_group_label>Edoxaban-based Regimen</arm_group_label>
    <arm_group_label>VKA-based Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria : Inclusion Criteria:

          -  Meets protocol-specified criteria for qualification and contraception

          -  Is willing and able to comply with any restrictions related food, drink and
             medications

          -  Voluntarily consents to participate and provides written informed consent prior to
             any protocol-specific procedures

        Exclusion Criteria:

          -  Has history or current use of over-the-counter medications, dietary supplements, or
             drugs (including nicotine and alcohol) outside protocol-specified parameters

          -  Has signs, symptoms or history of any condition that, per protocol or in the opinion
             of the investigator, might compromise:

               1. the safety or well-being of the participant or study staff

               2. the safety or well-being of the participant's offspring (such as through
                  pregnancy or breast-feeding)

               3. the analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Unverdorben (Professor of Medicine), MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Daiichi Sankyo Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Karatzous, BS, MS</last_name>
    <phone>+1 518 608 5129</phone>
    <email>Maria.Karatzou@Chiltern.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kay Price, PhD, ARNP</last_name>
    <phone>+1 423 990 0303</phone>
    <email>Kay.Price@Chiltern.com</email>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 31, 2016</lastchanged_date>
  <firstreceived_date>October 21, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter Aortic Valve Implantation -- TAVI</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>ENVISAGE-TAVI-AF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Phenprocoumon</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
